CD38 and plasma cell myeloma: Daratumumab (DARA)is a first-in-class anti-CD38 human IgG1κ monoclonal antibody (MoAb) that is effective in treating relapsed/refractory multiple myeloma both as monotherapy and in combination with proteasome inhibitors and immunomodulatory drugs [5,6].The clonal plasma cells in AL amyloidosis express CD38, thus making DARA a potentially effective treatment [7].